AlzeCure Pharma logo

Loading..
Svenska
Svenska
  • News
    News
      • Upcoming events
      • Subscribe
  • About us
    About us
      • AlzeCure Pharma in brief
      • Mission, vision & strategy
      • A word from the CEO
      • Organization
        • Management team
        • Board of directors
        • Founders
        • Scientific advisors
        • Collaborations and Partnership
      • History
      • Career
        • Open positions
  • Research & development
    Research & development
      • Project portfolio
      • NeuroRestore
      • Alzstatin
      • Alzheimer’s disease
      • Depression
      • Painless
        • ACD440
        • TrkA-NAM
      • Pain
      • Small molecules
      • Publications
      • The patients story
  • Governance
    Governance
      • Corporate Governance Reports
      • General meeting
        • General meetings
      • Nomination Committee
      • Board of directors
      • Management team
      • Remuneration
      • Auditors
      • Articles of association
  • Investors
    Investors
      • Share Issue 2024
      • Capital Markets Day 2023
      • AlzeCure Pharma on First North Premier Growth Market
        • Certified Adviser
      • Prospectuses
        • Share Issue 2024
        • Rights Issue December 2022
        • Rights Issue 2022
        • Listing prospectus 2018
      • The share
        • Trading information
        • Sharecapital development
        • Dividend policy
        • Ownership structure
        • Insiders
        • Analyst Coverage
      • Financial reports
      • Financial calendar
      • Presentations and Interviews
      • Press releases
      • Subscribe
      • Contact
  • Media
    Media
      • Press releases
      • Presentations and Interviews
      • Video gallery
      • Image bank
        • Board of directors
        • Management
        • Founders
        • Logotype
      • Financial calendar
      • Subscribe
      • Contact
  • Subscribe
  • Contact
    Contact
      • Office
      • Investors
      • Media

Press releases

All pressreleases
  • Regulatory press releases
  • Other press releases
2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • All years
May 14, 2025

Communiqué from the annual general meeting of AlzeCure Pharma on 14 May 2025

May 5, 2025

AlzeCure publishes its interim report for January – March 2025

April 9, 2025

Notice to Annual General Meeting in AlzeCure Pharma AB

April 7, 2025

New data bolstering the anti-inflammatory effect of NeuroRestore ACD856 presented at Alzheimer’s conference

April 3, 2025

AlzeCure Pharma publishes its Annual Report for 2024

April 2, 2025

New scientific article in Nature linking the potential use of NeuroRestore ACD856 for the treament of obesity

April 1, 2025

AlzeCure Pharma to present at Redeye Theme: Alzheimer & Parkinsons on April 8

February 27, 2025

AlzeCure publishes its Year-end report for January – December 2024

February 24, 2025

New article showing the unique mechanism of action behind Alzstatin as an Alzheimer’s treatment

February 17, 2025

AlzeCure receives EU grant for Phase 2 clinical trial of NeuroRestore ACD856 for Alzheimer’s disease

January 21, 2025

AlzeCure receives abstract acceptance at Alzheimer’s congress AD/PD 2025 on NeuroRestore ACD856

  • Media
    • Press releases
    • Presentations and Interviews
    • Video gallery
    • Image bank
      • Board of directors
      • Management
      • Founders
      • Logotype
    • Financial calendar
    • Subscribe
    • Contact
Mikael Widell
Mikael Widell
Head of Communications and IR
[email protected]
+46 703 11 99 60
About us
  • AlzeCure Pharma in brief
  • Mission, Vision & Strategy
  • A word from the CEO
  • Organization
  • Career
  • History
Research & development
  • Project portfolio
  • NeuroRestore
  • Alzstatin
  • Alzheimer’s disease
  • Depression
  • Painless
  • Pain
  • Small molecules
  • Publications
  • The patients story
Governance
  • Corporate Governance Reports
  • General meeting
  • Nomination Committee
  • Board of directors
  • Management team
  • Remuneration
  • Auditors
  • Articles of association
Investors
  • Share Issue 2024
  • Capital Markets Day 2023
  • AlzeCure Pharma on First North Premier Growth Market
  • Prospectuses
  • The share
  • Financial reports
  • Financial calendar
  • Presentations and Interviews
  • Press releases
  • Subscribe
  • Contact
Media
  • Press releases
  • Presentations and Interviews
  • Video gallery
  • Image bank
  • Financial calendar
  • Subscribe
  • Contact
Contact
  • Office
  • Investors
  • Media

AlzeCure Pharma AB, Hälsovägen 7,  SE-141 57 Huddinge, Sweden. Registration number: 559094-8302.

  • Follow us on LinkedIn
  • About cookies
  • Privacy policy for Alzecure Pharma